Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 1937 - 1944 of 12026 results

House Speaker Turmoil Flashes Warning Lights For Muni Advocates
January 6, 2023| News

Google LLC Agrees To Settle Privacy Class Action For $391.5M
January 6, 2023| News

Ensuring a Safe Haven for a Sexual Assault Survivor
January 6, 2023| Article| Viewpoint

USCIS Extends Green Card Validity for Naturalization Applicants
January 5, 2023| Alert| Viewpoint

Department of State provides option of four-year TN Visa for Mexican Citizens
January 5, 2023| Blog| Viewpoint

Litigators Weigh In With What To Watch For In 2023
January 5, 2023| News

IP Strategies for 2023 Informed by Top 2022 IP Issues
January 5, 2023| Blog| Viewpoint

Data Center Real Estate 2023: Experts Predict Development Slowdown, More Power Problems
January 5, 2023| News
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
The Evolving Global Digital Infrastructure: Data Centers, AI, and the Next Wave of Connectivity
New York, NY
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
